Every drug asset, with the evidence graded
A due-diligence terminal that grades the evidence behind every drug asset: trial design, size, endpoints and blinding, with the rubric published and the reasoning shown.
2,560
Drug assets
1,142
Companies
29
Indications
87,736
Registry studies
2,063
Graded trials
Browse by therapeutic area
Cardiometabolic Disease
$1473.3B attributable cost
$187.9B drug spend
344 assets · 4 diseases
Cardiovascular Disease
$756.0B attributable cost
$66.4B drug spend
293 assets · 3 diseases
Neurology
$704.8B attributable cost
461 assets · 6 diseases
Ophthalmology
$486.2B attributable cost
$9.7B drug spend
33 assets · 1 disease
Immunology
$429.0B attributable cost
296 assets · 6 diseases
Respiratory
$155.9B attributable cost
$66.5B drug spend
128 assets · 2 diseases
Infectious Disease
$59.5B attributable cost
$46.2B drug spend
61 assets · 1 disease
Pain
$56.9B attributable cost
16 assets · 1 disease
Oncology
$53.2B attributable cost
982 assets · 4 diseases
Upcoming phase-3 readouts
- August 2026BexicaserinEpilepsy · H. Lundbeck
- August 2026CamizestrantHR+/HER2- Metastatic Breast Cancer · AstraZeneca
- August 2026PalbociclibHR+/HER2- Metastatic Breast Cancer · Pfizer
- August 2026stapokibartAtopic Dermatitis · CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- August 2026ElranatamabMultiple Myeloma · Pfizer
- August 2026efsubaglutide alfaObesity · Shanghai Yinnuo Pharmaceutical Technology